FDA to review Merck's HPV vaccine

FDA accepted for review a BLA from Merck & Co. Inc. (NYSE:MRK) for V503 to prevent HPV infection. Merck declined to disclose when it expects a decision on the nonavalent HPV vaccine. V503 would vaccin...